Table 2.
Anti-cancer strategies overcoming drug-resistance in FGFR-positive tumors.
| Class of Drug | Name | Eliminating Resistance to | Cancer Type | References |
|---|---|---|---|---|
| Chemical inhibitors | AZD4547 | Gefitinib | NSCLC | [82] |
| PLX51107 | Melanoma | [199] | ||
| Tamoxifen | Breast cancer | [203] | ||
| PD173074 | ||||
| Gefitinib | NSCLC | [83] | ||
| Lapatinib | ESCC | [200] | ||
| Cisplatin | SCLC | [201] | ||
| Bevacizumab | HNSCC | [53] | ||
| Pemetrexed | Lung cancer | [176] | ||
| Doxorubicin | Endometrial cancer | [202] | ||
| Paclitaxel | ||||
| NSCLC | [205] | |||
| Epidermoid carcinoma | [204] | |||
| Vincristine | ||||
| Erdafitinib (JNJ-42756493) | Colchicine | [206] | ||
| ASP5878 | Gemcitabine | Urothelial cancer | [153] | |
| Doxorubicin | ||||
| BGJ398 (Infigratinib) | Paclitaxel/carboplatin | Ovarian cancer | [208] | |
| 5-fluorouracil | Colorectal cancer | [52] | ||
| Oxaliplatin | ||||
| Imatinib | GIST | [46] | ||
| Doxorubicin | [212] | |||
| Gefitinib | NSCLC | [213] | ||
| Alofanib | Paclitaxel/carboplatin | Ovarian cancer | [211] | |
| LY2874455 | Vemurafenib | Melanoma | [47] | |
| Ki23057 | Irinotecan | Gastric cancer | [214] | |
| Paclitaxel | ||||
| Etoposide | ||||
| Ligand trap | Suramin | Doxorubicin | Prostate cancer | [218] |
| miRNAs | miR-205 | Paclitaxel/doxorubicin/cyclophosphamide | Breast cancer | [223] |
| miR-3116 | Temozolomide | Glioma | [57] |